Brief: IO Biotech Announces Third Clinical Collaboration With Merck To Evaluate IO102-IO103 in Combination With KEYTRUDA

IO Biotech

06/12/2021 15:25

Dec 6 (Reuters) - IO Biotech Inc  IOBT.O :
    * IO BIOTECH ANNOUNCES THIRD CLINICAL COLLABORATION WITH
MERCK TO
EVALUATE IO102-IO103 IN COMBINATION WITH KEYTRUDA®
(PEMBROLIZUMAB) AS FIRST-LINE TREATMENT IN A PHASE 2 MULTI-ARM
BASKET TRIAL
    * IO BIOTECH INC - PURPOSE OF COLLABORATION IS TO EVALUATE
IO
BIOTECH'S LEAD CANDIDATE, IO102-IO103, IN COMBINATION WITH
KEYTRUDA (PEMBROLIZUMAB)
    * IO BIOTECH INC - PLANNED PHASE 2 TRIAL WILL EVALUATE
SAFETY AND
EFFICACY OF COMBINATION OF IO102-IO103
    * IO BIOTECH INC - IO BIOTECH WILL SPONSOR PHASE 2 TRIAL AND
MERCK
WILL SUPPLY PEMBROLIZUMAB

Source text for Eikon:  ID:nGNX16ZQBj 
Further company coverage:  IOBT.O 

 ((Reuters.Briefs@thomsonreuters.com;))